Send to

Choose Destination
Anticancer Res. 2016 Nov;36(11):6051-6057.

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations.

Author information

Society for the Coordination of Research, Algajola, France
Association of Research and Development Center for the Therapeutic Use of Organo-Metallic Compounds, Polyclinic Maymard, Bastia, France.
Laboratory of the Corsican Office of Hydraulic Equipment, Bastia, France.
SMARTc - Simulation and Modeling: Adaptative Response for Therapeutics in Cancer, UMR INSERM 911, Faculty of Pharmacy University of Aix-Marseille, Marseille, France.
UMR CNRS 8612, Galien Institute, Faculty of Pharmacy, University Paris-Saclay, Ch√Ętenay-Malabry, France.


Rhenium (I)-diselenoether has shown promising antiproliferative efficacy in both in vitro and in vivo models. However, the maximal tolerated dose and dose-effect relationships have not been fully addressed for this compound. Here, we evaluated the tolerance and efficacy of three dose-levels (namely 10, 40 and 100 mg/kg) intraperitoneally administered daily over 28 days in mice bearing the resistant MDA-MB231 breast cancer cell line. The upper dose was found to be toxic and was reduced to 60 mg/kg. The 10 mg/kg dose well tolerated, whereas 40 mg/kg was associated with 10% mortality (LD10). Both 10 and 40 mg/kg dosing achieved a significantly similar regression of tumor growth compared with untreated animals. This study suggests that 10 mg/kg daily is the recommended dose for rhenium (I) diselenoether.


MDA-MB231; Rhenium (Re); bioluminescence; breast cancer; in vivo experiment; mice; selenium (Se)

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center